ライフサイエンスコーパス: cysteinyl

1 cysteinyl-glycinyl bond of MCTR2 to give 13R-cysteinyl, 14S-hydroxy-4Z,7Z,9E,11E,13R,14S,16Z,19Z-doco

2 the 3-mercaptohexan-1-ol precursors and 4-S-cysteinyl-4-methylpentan-2-one.

3 inyl) as compared with native MSOX (8alpha-S-cysteinyl), a difference that may account for its approx

4 domain results in the formation of a flavin-cysteinyl adduct (LOV390) which thermally relaxes back t

5 vin protonation, which is common to both the cysteinyl adduct and the NSQ.

6 gen, voltage) protein, couples light-induced cysteinyl adduct formation at the flavin ring to conform

7 hain contributes to stabilization of the C-S cysteinyl adduct.

8 We report a method to enrich cysteinyl adducts of human serum albumin (HSA), represen

9 Elevated cysteinyl adducts to L-DOPA and DOPAC are seen early and

10 rcaptalbumin (i.e., unadducted HSA) from the cysteinyl adducts.

11 However, incubation of the enzyme with the cysteinyl adenylate analogue, 5'-O-[N-(l-cysteinyl)-sulf

12 y 5.2 s-1, respectively, consistent with the cysteinyl adenylate being a kinetically competent interm

13 zes the formation of a kinetically competent cysteinyl-adenylate intermediate after the addition of A

14 The approach utilizes the cysteinyl affinity resin to selectively enrich S-nitrosy

15 utamine forming external aldimine complexes, cysteinyl aldimine and glutaminyl aldimine.

16 othiol, i.e., 1-D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amido-2-deoxy-alpha-D-glucopyranoside (MSH or

17 othiol, i.e., 1-d-myo-inosityl-2-(N-acetyl-l-cysteinyl)amido-2-deoxy-alpha-d-glucopyranoside (MSH or

18 deacetylated, ligated with cysteine, and the cysteinyl amino group acetylated by acetyl-CoA to comple

19 compute spin densities on metal-coordinated cysteinyl and shed light on bonding changes as the Fe-C-

20 modified cysteine-flavin linkage (8-nor-8-S-cysteinyl) as compared with native MSOX (8alpha-S-cystei

21 endogenous activity was fully inhibited by a cysteinyl aspartate-specific protease-1-specific inhibit

22 Caspases are cysteinyl-aspartate proteases that function under apopto

23 Molecular modeling predicts formation of a cysteinyl-aurothiomalate adduct at Cys-69 that protrudes

24 de analogues, delta-(l-alpha-aminoadipoyl)-l-cysteinyl-beta-methyl-d-cyclopropylglycine and delta-(l-

25 muscle cell apoptosis, and MC and AAA lesion cysteinyl cathepsin expression and activities.

26 An imbalance between cysteinyl cathepsins and their principal endogenous inhi

27 Cysteinyl cathepsins have been implicated in multiple ma

28 Cysteine-cysteinyl chemokine receptor 4 (CCR4) is expressed by a

29 In contrast, substitution of Asp-157 with a cysteinyl coordination residue resulted in intact Cd2+ b

30 ine (ACG) and delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-alanine (ACA) with IPNS has previously been

31 ylglycine and delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-cyclopropylglycine, designed as probes for t

32 iol (BSH), the alpha-anomeric glycoside of L-cysteinyl-D-glucosamine with L-malic acid, is a major lo

33 he tripeptide delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-valine (ACV) to bicyclic isopenicillin N (IP

34 near tripeptide delta-L-alpha-aminoadipoyl-L-cysteinyl-D-valine (ACV) to isopenicillin N (IPN).

35 he tripeptide delta-(l-alpha-aminoadipoyl)-l-cysteinyl-d-valine (ACV).

36 ipeptide (from delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine synthetase).

37 in cysteine some of which reacts to form 5-S-cysteinyl-Dopa cross-links during the setting process.

38 LAR converts 4beta-(S-cysteinyl)-epicatechin back to epicatechin, the starter

39 insoluble PAs, and accumulation of 4beta-(S-cysteinyl)-epicatechin, which provides the 4-->8 linked

40 in that contains covalently bound FAD [8a-(S-cysteinyl)FAD] and catalyzes the oxidation of sarcosine

41 es the endogenous TSOX adduct and known 4a-S-cysteinyl flavin adducts.

42 iron-sulfur cluster ([4Fe-4S](2+)) and a 6-S-cysteinyl flavin mononucleotide (6-S-Cys-FMN) as redox c

43 ore and undergo photochemistry indicative of cysteinyl-flavin adduct formation.

44 ght through the photochemical formation of a cysteinyl-flavin covalent adduct.

45 s the tripeptide glutathione (gamma-glutamyl-cysteinyl-Gly) were found to be strong agonists of the G

46 ate analogues delta-(l-alpha-aminoadipoyl)-l-cysteinyl-glycine (ACG) and delta-(l-alpha-aminoadipoyl)

47 rved the S-4-mercapto-4-methylpentan-2-one-l-cysteinyl-glycine (CysGly-4MMP) and S-4-mercapto-4-methy

48 rotective thiols (cysteine, glutathione, and cysteinyl-glycine) and lactate from astrocytes.

49 Glutathione (gamma-glutamyl-cysteinyl-glycine, GSH) is a major thiol-containing pept

50 as mediated by dipeptidases that cleaved the cysteinyl-glycinyl bond of MCTR2 to give 13R-cysteinyl,

51 or other thiol-hydroquinones, for example, S-cysteinyl-hydroquinone, as substrates.

52 ilon)-D-cysteinyl-L-lysine, and N(epsilon)-L-cysteinyl-L-lysine into recombinant proteins in Escheric

53 epsilon)-L-thiaprolyl-L-lysine, N(epsilon)-D-cysteinyl-L-lysine, and N(epsilon)-L-cysteinyl-L-lysine

54 We have applied this cysteinyl-labeling assay to the study of platelet-derive

55 We anticipate that this cysteinyl-labeling enrichment strategy can be applied br

56 Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary

57 il infiltration, and increased levels of the cysteinyl leukotriene (cys-LT) leukotriene C(4) (LTC(4))

58 ) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production.

59 Tryptase and cysteinyl leukotriene (cysLT) levels were measured in na

60 Cysteinyl leukotriene (cysLT) overproduction is a hallma

61 human mast cell line (LUVA) as determined by cysteinyl leukotriene (CysLT) production.

62 We found that both cysteinyl leukotriene (CysLT) receptors, CysLT(1) and Cy

63 model is reversible by administration of the cysteinyl leukotriene (CysLT)1 receptor antagonist monte

64 patients with asthma and may participate in cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synt

65 tors occurs during EIB and how histamine and cysteinyl leukotriene antagonists alter the airway event

66 The paracrine signal was identified as a cysteinyl leukotriene because 1) RNAi knockdown or pharm

67 The antioxidant GSH and the pro-inflammatory cysteinyl leukotriene C4 have been identified as key phy

68 The combination of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]) enhances TH2 cytokine p

69 st cell precursors and selectively increased cysteinyl leukotriene formation by mast cells in a manne

70 first time, that the phagosome is a site of cysteinyl leukotriene formation.

71 on the ability of oxidative stress to alter cysteinyl leukotriene generation.

72 ility (RVP) was demonstrated using a bespoke cysteinyl leukotriene induced rodent model.

73 d urinary leukotriene E(4) levels indicating cysteinyl leukotriene inflammation can differentiate LAB

74 ding the production of Th2 cytokines and the cysteinyl leukotriene LTC(4).

75 ompared with their classic substrates in the cysteinyl leukotriene metabolome.

76 polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway

77 This resulted in further cysteinyl leukotriene production, triggering a positive

78 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT(1)R) are efficacio

79 oth murine and human fibrocytes express both cysteinyl leukotriene receptor (CysLT) 1 and CysLT2.

80 Furthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostan

81 bute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).

82 "proatopic" neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced

83 human T(H)2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA.

84 We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expr

85 TH2 cells, and montelukast, an antagonist of cysteinyl leukotriene receptor 1.

86 s and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln

87 Stimulation of the cysteinyl leukotriene receptor activated CRAC channels a

88 zed by some as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive

89 stigated the effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatm

90 The use of cysteinyl leukotriene receptor antagonists (LTRAs) for a

91 y, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.

92 ve characterized the gene structure of human cysteinyl leukotriene receptor type I (cysLT(1)R).

93 ing montelukast (an antagonist of the type 1 cysteinyl leukotriene receptor) also inhibited E. coli i

94 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) co

95 e inflammatory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and Cy

96 antiangiogenic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysL

97 rectly target VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at mi

98 ammatory factor that acts on plasma membrane cysteinyl leukotriene receptors.

99 rus expression, T-cell death, and eosinophil cysteinyl leukotriene release.

100 diating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor (CysLT1R), have no

101 inic and H1 histamine receptor and expressed cysteinyl leukotriene type 1 receptor in human embryonic

102 G-protein-coupled cysteinyl leukotriene type I (CysLT1) receptors regulate

103 t cytoplasmic Ca(2+) oscillations induced by cysteinyl leukotriene type I receptor activation run dow

104 ations can be evoked by modest activation of cysteinyl leukotriene type I receptors by the physiologi

105 The cysteinyl leukotriene type I receptors desensitize throu

106 Here, we show that following stimulation of cysteinyl leukotriene type I receptors in rat basophilic

107 3) RNAi knockdown of cysteinyl leukotriene type I receptors on resting cells

108 2) Block of cysteinyl leukotriene type I receptors on resting mast c

109 tion of partner receptors (nucleotide P2Y12, cysteinyl-leukotriene CysLT1) to reconstitute the elusiv

110 s in s/s mice were associated with increased cysteinyl-leukotriene production in vivo and in AMs in v

111 mice could be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.

112 1/2, cytosolic phospholipase A(2) alpha, and cysteinyl-leukotriene synthesis confers resistance to s/

113 educes antigen-induced secretion of PGD2 and cysteinyl-leukotriene.

114 decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated

115 The cysteinyl leukotrienes (cys-LTs) are 5-lipoxygenase path

116 The cysteinyl leukotrienes (cys-LTs) are a family of potent

117 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory

118 The cysteinyl leukotrienes (cys-LTs) are proinflammatory lip

119 The cysteinyl leukotrienes (cys-LTs) are three structurally

120 Cysteinyl leukotrienes (cys-LTs) can mediate Th2 immunit

121 receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils.

122 Cysteinyl leukotrienes (cys-LTs) induce inflammation thr

123 Cysteinyl leukotrienes (cys-LTs) induce inflammatory res

124 The cysteinyl leukotrienes (cys-LTs), leukotriene C4 (LTC4),

125 stimulated a rapid and robust production of cysteinyl leukotrienes (cys-LTs), proinflammatory lipid

126 Although arachidonic acid metabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C4, LT

127 ion was evaluated as Ca2+ flux, secretion of cysteinyl leukotrienes (CysLT), and eosinophil-derived n

128 Because cysteinyl leukotrienes (cysLTs) are also produced during

129 Cysteinyl leukotrienes (cysLTs) are bronchoconstricting

130 Cysteinyl leukotrienes (cysLTs) are important mediators

131 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators deri

132 Cysteinyl leukotrienes (CysLTs) are potent lipid mediato

133 Leukotriene E4 (LTE4) the most stable of the cysteinyl leukotrienes (cysLTs) binds poorly to classica

134 Cysteinyl leukotrienes (CysLTs) contribute to asthma pat

135 Cysteinyl leukotrienes (cysLTs) facilitate mucosal type

136 nstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma media

137 ctures show that the N-terminal domain binds cysteinyl leukotrienes (cysLTs) with high affinities (50

138 Cysteinyl leukotrienes (cysLTs), 5-lipoxygenase pathway

139 r of the airways, involves overproduction of cysteinyl leukotrienes (cysLTs), activation of airway ma

140 thma, tissue eosinophilia, overproduction of cysteinyl leukotrienes (cysLTs), and respiratory reactio

141 eukotriene E4 (LTE4), the most stable of the cysteinyl leukotrienes (cysLTs), binds poorly to classic

142 Large amounts of cysteinyl leukotrienes (cysLTs), classically known as a

143 In contrast, cysteinyl leukotrienes (cysLTs), important proinflammato

144 Cysteinyl leukotrienes (cysLTs), including leukotriene (

145 Cysteinyl leukotrienes (cysLTs), leukotriene C4 (LTC4),

146 is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in as

147 step in the formation of eicosanoids such as cysteinyl leukotrienes (CysLTs).

148 onstitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs).

149 capable of both producing and responding to cysteinyl leukotrienes (CystLTs), allowing for the killi

150 d lipoxygenase products of arachidonic acid, cysteinyl leukotrienes (LTs), contribute to E. coli K1 i

151 poxygenated metabolites of arachidonic acid, cysteinyl leukotrienes (LTs).

152 lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC4, LTD4, and LTE4), only

153 reatments being developed beyond blockade of cysteinyl leukotrienes and IgE and improvements in inhal

154 Cysteinyl leukotrienes and oxidative stress have both be

155 ophagoides farinae through the generation of cysteinyl leukotrienes and proinflammatory cytokines, re

156 and suggest downstream provocative roles for cysteinyl leukotrienes and protective roles for SOCS3 in

157 AM phagocytosis, killing, and production of cysteinyl leukotrienes and TNF-alpha are restored in the

158 Cysteinyl leukotrienes are established mediators of bron

159 Our findings that cysteinyl leukotrienes are involved in regulating airway

160 Cysteinyl leukotrienes are involved in the pathogenesis

161 Cysteinyl leukotrienes are primarily produced by mast ce

162 feedback cascade involving CRAC channels and cysteinyl leukotrienes constitute a novel mechanism for

163 Cysteinyl leukotrienes contribute to Th2-type inflammato

164 Cysteinyl leukotrienes D(4) and E(4) and PGD(2) also ind

165 Herein we report that uracil nucleotides and cysteinyl leukotrienes do not activate human, mouse, or

166 Measurement of the release of histamine and cysteinyl leukotrienes documented that this bronchoprote

167 Using immunostaining for the cysteinyl leukotrienes in carbodiimide-fixed cells, we s

168 We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficki

169 entify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary traff

170 associated with the levels of histamine and cysteinyl leukotrienes in the airways.

171 farinae-elicited IL-6, IL-23, TNF-alpha, and cysteinyl leukotrienes in the lung.

172 ccompanied by a surge in bronchoconstrictory cysteinyl leukotrienes produced at the expense of LTB4 i

173 exercise challenge, histamine, tryptase, and cysteinyl leukotrienes significantly increased and prost

174 We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cel

175 bstance of anaphylaxis was composed of three cysteinyl leukotrienes that act in the inflammatory resp

176 ut the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the t

177 GE2 were reduced in COX-1-/- airways whereas cysteinyl leukotrienes were elevated in COX-2-/- airways

178 sharp contrast, mean levels of prophlogistic cysteinyl leukotrienes were increased in samples from se

179 ablysin-15 was found to bind proinflammatory cysteinyl leukotrienes with submicromolar affinities.

180 Prominent among such signals are the cysteinyl leukotrienes, a family of potent proinflammato

181 ncreases in metabolites of prostaglandin D2, cysteinyl leukotrienes, and isoprostanes following the c

182 proinflammatory mediators, including IL-13, cysteinyl leukotrienes, and PGD(2), and airway hyperresp

183 to produce LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma.

184 , ATLa treatment led to marked reductions in cysteinyl leukotrienes, interleukin-4 (IL-4), and IL-10,

185 cts: 5-,12-,15-hydroxyeicosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thro

186 Pharmacological inhibition of cysteinyl leukotrienes, lipoxygenated products of arachi

187 triad of preclinical areas of investigation-cysteinyl leukotrienes, mast cells, and complement-with

188 abolites of vasoactive molecules showed that cysteinyl leukotrienes, prostacyclin metabolites, and PG

189 The de novo synthesis of cysteinyl leukotrienes, TNFalpha, CXCL8, CCL2, CCL3, and

190 LTC4 is the parent molecule of the cysteinyl leukotrienes, which are recognized for their p

191 ial killing, and production of TNF-alpha and cysteinyl leukotrienes.

192 , whereas mRECs produced both LTB(4) and the cysteinyl leukotrienes.

193 nflux through CRAC channels and responded to cysteinyl leukotrienes.

194 ntrast, M1 macrophages gave higher levels of cysteinyl leukotrienes.

195 piratory tissues and excessive production of cysteinyl leukotrienes.

196 cterise the responsiveness of human P2Y12 to cysteinyl leukotrienes.

197 -IgE or SCF and the generation of histamine, cysteinyl-leukotrienes (cys-LTs) and prostaglandin D(2)

198 itis model accompanied by impaired levels of cysteinyl-leukotrienes and prostaglandin E2.

199 The synthesis of cysteinyl-leukotrienes was reduced and that of PGE(2) en

200 classes of molecules: uracil-nucleotides and cysteinyl-leukotrienes.

201 re, where a ferric ion and four coordinating cysteinyl ligands are arranged into a distorted tetrahed

202 NOEs between the beta-CH(2) protons of Zn cysteinyl ligands are consistent with a strand-swapped H

203 enzymes and supports the involvement of non-cysteinyl ligands in the coordination of auxiliary clust

204 he [2Fe-2S] cluster, the Sgamma atoms of the cysteinyl ligands, and the backbone amide nitrogen atoms

205 -4S](2+) cluster that is coordinated by four cysteinyl ligands, two of which are adjacent in the amin

206 [4Fe-4S] cluster cofactor with a unique, non-cysteinyl-ligated, iron ion (Fea), which is proposed to

207 ditional requirement for a catalytic base in cysteinyl ligation.

208 y in the literature for analyzing interchain cysteinyl-linked ADCs are either not amenable to online

209 nce method for quality control of interchain cysteinyl-linked ADCs.

210 of B leukotriene type 1 (BLT1) receptor and cysteinyl LT type 1 (cysLT1) receptor, respectively.

211 of targeting vascular events in sepsis with cysteinyl-LT blockade.

212 C(4) synthase, LTB(4) receptors 1 and 2, and cysteinyl-LT receptors 1 and 2.

213 LO-activity inhibitor, or MK571, a selective cysteinyl-LT(1) receptor antagonist, largely prevented v

214 es (LTs) C4, D4, and E4, collectively termed cysteinyl LTs (cysLTs), are lipid mediators formed by th

215 demonstrated in vivo for LTB(4), but not for cysteinyl LTs (cysLTs).

216 teinyl LTs, suggesting that cPLA(2)alpha and cysteinyl LTs contribute to type III GBS invasion of the

217 ific host factors involving cPLA(2)alpha and cysteinyl LTs contribute to type III GBS penetration of

218 m subjects with AERD generated more LTB4 and cysteinyl LTs than did granulocytes from controls with a

219 abolished by inhibition of cPLA(2)alpha and cysteinyl LTs, suggesting that cPLA(2)alpha and cysteiny

220 Leukotriene B4 (LTB4) was more potent than cysteinyl LTs.

221 These data demonstrate opposing effects of cysteinyl-LTs on innate immune vs hemodynamic responses,

222 e enhanced accumulation of LTB(4) but not of cysteinyl-LTs.

223 The cysteinyl moiety at position 1 of the C-TAT peptide cont

224 ves the two-electron oxidation of a specific cysteinyl or seryl residue on the relevant sulfatase.

225 One AEDANS-cysteinyl-peptide fractionation strategy employs immobil

226 a functionally competent reducing agent for cysteinyl persulfide bond cleavage, releasing inorganic

227 ect the mechanism of formation of the enzyme cysteinyl persulfide intermediate in the reaction of a c

228 with the light-induced formation of a flavin-cysteinyl photoadduct.

229 The protein was found to contain a cysteinyl post-translational modification at Cys(214).

230 sed cathepsin K immunostaining and increased cysteinyl proteinase activity using near infrared fluore

231 radical (Y(122)*) in R2 generate a transient cysteinyl radical (C(439)*) in R1 through a pathway thou

232 es a cysteine residue in the R1 subunit to a cysteinyl radical (C*), which abstracts the 3'-hydrogen

233 Turnover requires formation of a cysteinyl radical (C439*) in the active site of alpha2 a

234 lectron from a cysteine residue to produce a cysteinyl radical.

235 In mitochondrial complex I, specific cysteinyl redox domains modulate ROS production from the

236 AO A contains a flavin covalently bound to a cysteinyl residue at C8alpha.

237 odification(s) of Cys-122, a beta(1)-subunit cysteinyl residue demonstrated previously to modulate NO

238 ord acyclic products, in which the substrate cysteinyl residue has undergone a two-electron oxidation

239 ng that the active metabolite is linked to a cysteinyl residue of CYP2B6 via a disulfide bond.

240 opidogrel and the covalent modification of a cysteinyl residue of human cytochrome P450 2B6 in a reco

241 e) catalyzes the two-electron oxidation of a cysteinyl residue on a cognate protein to a formylglycyl

242 re acylated with a (S)-(2,3-bisacyloxypropyl)cysteinyl residue.

243 pacer segments was achieved through a unique cysteinyl residue.

244 ure to acidic pH; thus, modification of free cysteinyl residues biochemically separated the process o

245 Cysteinyl residues important for Cu(I) binding are also

246 or separation and identification of modified cysteinyl residues in proteins have been developed, crit

247 Furthermore, mutation of key cysteinyl residues ligating the catalytic [Fe4S4] cluste

248 hes were used to assess the pK(a) of the two cysteinyl residues of AhpC.

249 This analysis identified cysteinyl residues of E1 and E2, which were found to be

250 Here we report studies on the reactivity of cysteinyl residues of the catalytic domain of PHD2 using

251 , which was consistent with the cytochrome c cysteinyl residues of the CXXCH motif requiring periplas

252 Among the seven cysteinyl residues of the PHD2 catalytic domain, Cys201

253 Site-directed mutagenesis of cysteinyl residues putatively required as ligands of the

254 This suggests that the modification of free cysteinyl residues results in the loss of infectivity by

255 pepsin at pH 2, a limited transfer to other cysteinyl residues was observed.

256 nature of this disulfide network, E1 and E2 cysteinyl residues were labeled with iodoacetamide in th

257 These species can harm/destroy cysteinyl residues, iron-sulphur clusters, DNA and polyu

258 bonds formed by protein backbone amides with cysteinyl S(gamma) atoms play important roles in modulat

259 Cysteinyl S-nitrosylation has emerged as an important po

260 t of LP-BM5-infected mice with N-(N-acetyl-l-cysteinyl)-S-acetylcysteamine (I-152), an N-acetyl-cyste

261 he N-acetyl-p-benzoquinoneimine metabolite L-cysteinyl-S-acetaminophen was detected in the mouse spin

262 by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compounds are potential va

263 -S-(2,3-bis(palmitoyloxy)-(2R,S)-propyl)-(R)-cysteinyl-seryl-(l ysyl)3-lysine (Pam3CysSK4), a synthet

264 prepare circular proteins with or without a cysteinyl side chain.

265 structural consequences of their binding to cysteinyl side chains in proteins, remain poorly underst

266 g that the pro-S hydrogen atom of the normal cysteinyl substrate is stereoselectively removed during

267 ght binding bisubstrate analogue, 5'-O-[N-(L-cysteinyl)sulfamonyl]adenosine (CSA), has suggested spec

268 A stable bisubstrate analogue, 5'-O-[N-(l-cysteinyl)sulfamonyl]adenosine, exhibits competitive inh

269 the cysteinyl adenylate analogue, 5'-O-[N-(l-cysteinyl)-sulfamonyl]adenosine (CSA), followed by a 24-

270 llagen 4-hydroxyproline content and enhanced cysteinyl sulfenic acid modification of ER proteins.

271 st that reduction-oxidation modifications of cysteinyl sulfhydryl groups in mature ADAM17 may serve a

272 itions of increased oxidant stress confirmed cysteinyl sulfinic acid (m/z 435), sulfonic acid (m/z 44

273 tachment; (ii) to spatially position the two cysteinyl sulfurs adjacent to the two heme vinyl groups

274 onstrate that aldosterone modulates an ET(B) cysteinyl thiol redox switch to decrease pulmonary endot

275 They further indicate that H bonds to the cysteinyl thiolate sulfur ligand reduce the spin density

276 ecies production, which oxidatively modified cysteinyl thiols in the eNOS-activating region of ET(B)

277 Quantitation of the redox status of cysteinyl thiols within ER-DBD employed cysteine-specifi

278 o coordinate 7 Zn(2+) or Cd(2+) ions with 20 cysteinyl thiols, will bind 8 structurally significant C

279 ing covalent bonds with nucleophiles such as cysteinyl thiols.

280 Several methanogenic archaea lack cysteinyl-transfer RNA (tRNA) synthetase (CysRS), the es

281 for protein synthesis using both a canonical cysteinyl-tRNA synthetase (CysRS) as well as a set of tw

282 Human cysteinyl-tRNA synthetase (CysRS) does not associate wit

283 t aminoacylation of tRNA by Escherichia coli cysteinyl-tRNA synthetase (CysRS) requires both domains,

284 Cys)) in methanogens that lack the canonical cysteinyl-tRNA synthetase (CysRS).

285 synthetase (proS [mhp397]) (P = 0.009), and cysteinyl-tRNA synthetase (cysS [mhp661]) (P < 0.001) we

286 ynthetases SepRS (forming Sep-tRNA(Cys)) and cysteinyl-tRNA synthetase (forming Cys-tRNA(Cys)).

287 on factor 2, cell division protein FtsZ, and cysteinyl-tRNA synthetase as immunoreactive proteins.

288 association was also identified at the CARS (cysteinyl-tRNA synthetase) locus (OR = 1.36, P = 3.1 x 1

289 with phosphoserine (Sep), and the well known cysteinyl-tRNA synthetase, which charges the same tRNA w

290 tertiary fold of MshC is similar to that of cysteinyl-tRNA synthetase, with a Rossmann fold catalyti

291 ction catalyzed by prokaryotic and mammalian cysteinyl-tRNA synthetases (CARSs).

292 that is unique to several halophile archaeal cysteinyl-tRNA synthetases (CysRS), which catalyze attac

293 uggests similarities and differences between cysteinyl-tRNA synthetases and MshC in recognition of th

294 of tRNA-bound O-phosphoserine (Sep) to form cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) in methanogens that

295 ubset of methanogenic archaea synthesize the cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) needed for protein s

296 Synthesis of cysteinyl-tRNA(Cys) in methanogenic archaea proceeds by

297 sS, which converts phosphoseryl-tRNA(Cys) to cysteinyl-tRNA(Cys) in nearly all methanogens.

298 teine to tRNA(Cys) to generate the essential cysteinyl-tRNA(Cys) required for protein synthesis.

299 ar iron center and the catalytic role of the cysteinyl-tyrosine linkage.

300 Cysteinyl variants on the alpha3 and L3 regions, which f

301 with the intrinsic reactivity of Cys-SSH for cysteinyl versus sulfur transfer, are consistent with th